Background: Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission tomography (PET) after two to three cycles of chemotherapy may inform therapeutic decisions. Risk stratification at diagnosis could, however, allow earlier and potentially more efficacious treatment modifications.
INTRODUCTION
Hodgkin lymphoma (HL) is a highly curable malignancy, but the extent of treatment necessary for the individual patient differs across the population. [1] [2] [3] [4] Significant risks (late toxicities [5] [6] [7] [8] [9] [10] [11] vs. recurrence 12, 13 ) are associated with over-and undertreatment. Therefore, it is critical to examine methods of allocation to treatment strata that are optimally tailored to disease extent and biology. Although early response to initial chemotherapy as measured by computed tomography (CT) and/or positron emission tomography (PET) has proven useful in allocating patients to subsequent therapy 1, 3 (e.g., elimination of radiotherapy and augmentation of chemotherapy), risk stratification at diagnosis may allow earlier modification of the treatment approach. Until recently, selection of HL treatment regimens was based primarily on stage and B symptoms, occasionally with the addition of other clinical factors recognized as univariate predictors of outcome. The International Prognostic Score, 14 developed based on multivariable analysis using a large cohort of adults with advanced-stage disease, has been used to identify risk but includes predictors that are not applicable to the pediatric/adolescent population. Pediatric studies that explored clinical features as multivariate factors were limited by cohort size and heterogeneity of treatments. [15] [16] [17] Because a prognostic score for event-free survival (EFS) in pediatric/adolescent HL represents an important gap in knowledge that can impact patient outcome, we evaluated a large cohort of children and adolescents receiving uniform treatment for intermediate-risk HL. This has provided opportunity to identify predictors of EFS in HL based on clinical factors known at diagnosis and to develop a prognostic score using these factors.
METHODS

Patients and treatment
AHOD0031 was an intergroup study including patients from the Chil- with filgrastin 5 g/kg daily days 6, 7, and 9 and until count recovery (modified from Schwartz). 3 After two cycles, CT scan defined rapid early responders (RERs) with a 60% reduction in tumor size versus the slow early responders (SERs). Detailed information can be found in the primary study report. 1 The "standard" therapy was four cycles of ABVE-PC plus 21
Gy involved field radiation therapy (IFRT). Central review of early response was performed for RER who achieved complete response (CR) and for all patients beginning in 2006. With evolution of imaging techniques, PET scans became the usual choice of physicians. The study was completed before the Deauville criteria 18 were defined in 2009; institutions therefore considered PET to be negative if there was definitive resolution of PET activity using qualitative measures. At the time of data analysis, PET scans read institutionally as equivocal prior to Deauville were re-evaluated at the Quality Assurance Review Center (Providence, RI) and assigned as negative if the Deauville score (DS) was ≤ 2.
Patient cohorts for analyses
The study population for predictive modeling included patients ran- A secondary analysis was performed to evaluate whether use of early response by PET or CT might provide information that would mitigate the utility of the CHIPS. This analysis included all patients in the training and validation cohorts who had both PET and CT response reported after course 2 and data available to determine the CHIPS prognostic score.
Statistical analysis
Clinical variables available within the COG database were included in the univariate analysis. Continuous variables were dichotomized based on clinical significance and/or quartiles of the cohort. Class variables were evaluated to identify subsets of the population with differential risks. Failures for EFS included disease relapse/progression, second malignancy, and death due to any cause. Time-to-event was computed from study enrollment; patients without failures were censored at date of last contact.
Cox proportional hazard model 19 was used for univariate and multivariable analyses of the clinical predictors of EFS. Multivariable predictive modeling and stepwise selection were performed with predictors having P ≤ 0.25 in univariate analysis. In instances of collinearity of predictors (e.g., bulk disease vs. large mediastinal mass), the most robust univariate variable was evaluated in the multivariable model. Analyses were performed using SAS 9.3.
CHIPS was devised using each factor associated with reduced EFS (from stepwise selection), with one point assigned to each relevant data available for all predictive factors comprising CHIPS were used in the analysis of EFS. P-values from the log rank test comparing the EFS curves defined by CHIPS were used to determine whether the survival curves between CHIPS levels were different.
RESULTS
Patients
A total of 1,712 of 1,734 patients enrolled on AHOD0031 were eligible for study (Fig. 1 ). Twenty-two were ineligible: 18 did not meet diagnosis criteria, one received pretreatment steroid, and three did not have required pretreatment evaluations. Early response was not reported in 74 patients; they were not subsequently randomized or assigned to protocol therapy. Patients assigned to experimental regimens (N = 535) were not included in this analysis, leaving 1,103 who received four cycles of ABVE-PC/IFRT and serve as the focus of this report. 
Development of CHIPS: Predictors identified in the cohort receiving 4 ABVE-PC + radiation therapy
All variables in the AHOD0031 database were considered for inclusion in the model. Table 1 Fever was used in further analyses because it was measurable and the most robust of the collinear variables.
A multivariable model was fit ( patients) had excellent 4-year EFS (93.1 ± 1.4 and 88.5 ± 1.6%, respectively) versus 77.6 ± 2.9% and 69.2 ± 6.5% for CHIPS 2 and 3 patients, respectively (Fig. 2) . Overall, 73% were patients with CHIPS 0 or 1 having a 4-year EFS of 90.6%. CHIPS 2 or 3 patients comprised 27%
CHIPS and EFS
of the combined cohort and had a 4-year EFS of 75.9%.
There were more patients with CHIPS 0 in the RER/CR than in the RER/no CR. SER had the fewest patients with CHIPS 0. Conversely, the SER had a larger percentage of CHIPS 2-3 than either RER cohort.
Overall, there was a trend for CHIPS to be lower for RER/CR versus RER/no CR (P < 0.001) and for RER versus SER (P < 0.0001). 
CHIPS and CT/PET
Data from the secondary analysis performed to evaluate whether the use of early response by PET or CT provided information that would mitigate the utility of the CHIPS are shown in Table 3 .
This analysis included all patients in the population (training and validation cohorts) who had both PET and CT response reported after course 2 and had data available to determine the CHIPS prognostic score. There were 704 patients who had data to calculate CHIPS and both CT and PET response after two cycles. A high-risk cohort was The benefit of using CHIPS versus early response based on CT and PET scan is clear in this cohort. While both approaches detected very small populations of patients (n = 34 with 59-60% EFS for either CHIPS 3 or PET/CT nonresponders), the former was better able to separate the larger population with reasonably good outcomes into CHIPS 0-1 with an outcome of >90% and CHIPS 2 with an outcome of 75%.
TA B L E 3 Four-year EFS for patients with CT and PET evaluation after two cycles
Early response could not separate cohorts with EFS of 88% for PET and CT responders or 85-88% for CT or PET responders. But even more important is the feasibility of defining a prognostic group at diagnosis rather than after two cycles, thus enabling earlier therapeutic modifications. Sposto considered a quantitative assessment of risks and benefits of treatment strategies, 21 noting that optimal "cut-points" in criteria for high-versus low-risk disease must be based on both the morbidity of augmentation therapy and incremental efficacy. In HL, potential gain in population outcome is achievable only by giving (i) minimally toxic/minimally beneficial treatment to a larger cohort or
DISCUSSION
(ii) more intensive/toxic therapy to a small high-risk cohort. The history of prognostic factors for HL reflects the process of therapeutic tailoring leading toward more uniform prognosis and subsequent restriction of the utility of these factors.
We used early-response-based therapy in our legacy 3 and COG 1 trials to tailor therapy for the individual. In the current trial (AHOD0031), we found that early-response could guide (i) reduction of therapy for RER by identifying patients without the need for IFRT and (ii) therapeutic augmentation with additional chemotherapy in SER. 1 Since tailoring of therapy occurred only after two or four cycles of standard chemotherapy, we sought to determine whether a cohort could be identified at diagnosis that might be targeted for earlier intensification or reduction of therapy.
AHOD0031 enrolled sufficient numbers of homogeneously treated patients to fully explore, with training and validation cohorts, the asso- Patients with CHIPS 0-1 had 90.5% 4-year EFS versus 76.9% for those with CHIPS 2-3. This differential in expected outcome can be defined at diagnosis, allowing for early implementation of tailored therapy.
Stage has been a highly relevant predictor of outcome in HL. In a small study of 69 children with newly diagnosed HL, stage IV disease was the only predictor of outcome determined by multivariable analysis. 22 Our larger study found additional factors. Early PET response to ABVD was evaluated by standardized uptake value in an early study by Hutchings 24 and more recently 25 by a DS of ≤3. PET scans on our study were investigational and not used for clinical decisions; a DS ≤ 2 identified early PET responders.
Since those with DS = 3 would have been in the PET nonresponders/CT responders cohort that had virtually identical outcomes to the PET responder/CT responder cohort, it is unlikely using a different DS criteria for evaluating PET response would have impacted our results.
The criteria for response assessment must be defined by the study goals. In trials designed to reduce therapy for responders, more stringent criteria for response may reduce risk of relapse while more lenient criteria will reduce therapeutic exposures. Similar decisions may ultimately be made in determining therapeutic allocation by CHIPS.
Our data suggest that in this cohort, CHIPS eliminated any benefit of early response assessment. Most important, however, is that it is known at diagnosis and therefore allows earlier intervention. The robustness of CHIPS is of relevance not only because it facilitates earlier identification of risk, but also because it suggests feasibility of eliminating the costly early PET/CT scans that are increasingly used for therapeutic determination in HL.
Even more critical than cost reduction in the developed nations is that CHIPS could potentially allow developing nations to incorporate an equivalently predictive risk-based therapeutic algorithms using accessible parameters (stage 4 disease, large mediastinal mass, albumin level, and fever), thus improving access to state-of-the-art care throughout the world. This would, however, require careful analysis of CHIPS in the context of different cohorts and with different treatment regimens. Our results are based on a specific treatment regimen and did not include either the lowest or highest stage patients.
While it likely is possible to augment therapy to the extent that this prognostic score (CHIPS) will no longer be predictive, it is our goal to preserve ability to identify cohorts with excellent outcomes that may be considered for therapeutic reduction. Further reduction of therapy in the three-fourth of the population with low CHIPS may be feasible if higher risk patients receive more optimal treatment.
CONCLUSION
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